Literature DB >> 9624495

Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model.

C Padoin1, M Tod, G Perret, O Petitjean.   

Abstract

Oligopeptidic drugs such as beta-lactams and angiotensin-converting enzyme inhibitors share the same carriers in humans and animals, which results in possible pharmacokinetic interactions. To model such interactions, the effects of quinapril on cephalexin pharmacokinetics were investigated in rats. Blood cephalexin concentrations were measured by liquid chromatography, and the data were analyzed by a noncompartmental method and by fitting a bicompartmental model by a nonlinear mixed-effect modeling approach. Five groups of eight rats were examined. In the first three groups, cephalexin elimination kinetics after intra-arterial administration alone or in combination with quinapril given by the parenteral or the oral route were studied, and the occurrence of a pharmacokinetic interaction was not revealed. The absence of an effect of quinapril on cephalexin elimination after parenteral administration might be explained either by the higher affinity of cephalexin for the renal anionic transport system than that of quinapril or by the much higher concentrations of cephalexin than those of quinapril. In the last two groups, cephalexin was administered by the oral route alone or in combination with quinapril. The mean area under the concentration-time curve (AUC) for cephalexin was increased by ca. 30% by coadministration of quinapril (40.1 versus 31.4 mg.h/liter; P = 0.04). The mean elimination clearance of cephalexin was significantly decreased by quinapril, from 0.81 to 0.64 liter/h/kg of body weight (P < 0.05), probably by competitive inhibition of cephalexin secretion at the tubular level. The mean absorption rate constant of cephalexin was significantly lowered by quinapril (from 0.249 to 0.177 h-1; P < 0.01), without modification of the extent of absorption (89%). This pharmacokinetic interaction could be explained by competitive inhibition of cephalexin active transport by quinapril at the intestinal level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624495      PMCID: PMC105623     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

Authors:  D B White; C A Walawander; D Y Liu; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

Review 2.  Population pharmacokinetics/dynamics.

Authors:  L B Sheiner; T M Ludden
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

3.  Saturable rate of cefatrizine absorption after oral administration to humans.

Authors:  B G Reigner; W Couet; J P Guedes; J B Fourtillan; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

4.  Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2.

Authors:  A H Dantzig; L Bergin
Journal:  Biochim Biophys Acta       Date:  1990-09-07

5.  The inhibitory effects of cephalosporin and dipeptide on ceftibuten uptake by human and rat intestinal brush-border membrane vesicles.

Authors:  M Sugawara; T Toda; M Kobayashi; K Iseki; K Miyazaki; H Shiroto; J Uchino; Y Kondo
Journal:  J Pharm Pharmacol       Date:  1994-08       Impact factor: 3.765

6.  Studies on the renal excretion mechanisms of cefadroxil.

Authors:  L Granero; M J Gimeno; F Torres-Molina; J Chesa-Jiménez; J E Peris
Journal:  Drug Metab Dispos       Date:  1994 May-Jun       Impact factor: 3.922

7.  Estimating bioavailability when clearance varies with time.

Authors:  M O Karlsson; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-06       Impact factor: 6.875

8.  Intestinal absorption of beta-lactam antibiotics and oligopeptides. Functional and stereospecific reconstitution of the oligopeptide transport system from rabbit small intestine.

Authors:  W Kramer; F Girbig; U Gutjahr; S Kowalewski; F Adam; W Schiebler
Journal:  Eur J Biochem       Date:  1992-03-01

9.  Nonlinearity of amoxicillin absorption kinetics in human.

Authors:  G Paintaud; G Alván; M L Dahl; A Grahnén; J Sjövall; J O Svensson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Transport characteristics of cephalosporin antibiotics across intestinal brush-border membrane in man, rat and rabbit.

Authors:  M Sugawara; T Toda; K Iseki; K Miyazaki; H Shiroto; Y Kondo; J Uchino
Journal:  J Pharm Pharmacol       Date:  1992-12       Impact factor: 3.765

View more
  7 in total

1.  Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen.

Authors:  E Tsivou; I Melakopoulos; A Kotsiou; S Anagnostopoulou; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

2.  Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.

Authors:  Kimberly L Garrison; Selma Sahin; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2015-05-25       Impact factor: 3.534

Review 3.  Review of Pharmacokinetic Data of Different Drug Classes in Goto-Kakizaki Rats, a Non-obese Model for Type 2 Diabetes Mellitus: Case Studies and Perspectives.

Authors:  Harilal Patel; Poonam Giri; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

4.  Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects.

Authors:  Rui Liu; Audrey May Yi Tang; Yen Ling Tan; Lie Michael George Limenta; Edmund Jon Deoon Lee
Journal:  Eur J Clin Pharmacol       Date:  2008-09-03       Impact factor: 2.953

5.  Dermal drug levels of antibiotic (cephalexin) determined by electroporation and transcutaneous sampling (ETS) technique.

Authors:  S M Sammeta; Siva Ram K Vaka; S Narasimha Murthy
Journal:  J Pharm Sci       Date:  2009-08       Impact factor: 3.534

6.  Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.

Authors:  Kei Nishizawa; Noriaki Yoda; Fumi Morokado; Hisakazu Komori; Takeo Nakanishi; Ikumi Tamai
Journal:  PLoS One       Date:  2019-04-05       Impact factor: 3.240

7.  The effect of cephalexin in influencing the pharmacokinetics of a novel drug - 5'-valyl-cytarabine hydrochloride.

Authors:  Xiaotong Song; Yinghua Sun; Chenyao Zhao; Zhonggui He
Journal:  Asian J Pharm Sci       Date:  2016-08-31       Impact factor: 6.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.